Ask AI
ProCE Banner Activity

Keeping Up With New Developments in PBC

Podcast Episodes

Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.

Released: October 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc.

Gilead Sciences, Inc.

Ipsen Biopharmaceuticals Inc

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new advances in PBC to clinical practice

  • Formulate patient management strategies based on up-to-date understanding of new and emerging agents for PBC, including mechanisms of action, clinical data, safety, and place in therapy

  • Integrate expert guidance and patient insights into treatment plans for PBC

Disclosure

Primary Author

Christopher L. Bowlus, MD: researcher (paid to institution): Calliditas, ChemoMab, COUR, Cymabay, Gilead, GSK, Hanmi, Ipsen, Mirum, Novartis, Pliant, Zydus; consultant/advisor/speaker: Alnylam, Amgen, AstraZeneca, ChemoMab, Esperion, Gilead, GSK, Ipsen, Kezar, Mirum, Pliant, Takeda.

Sonal Kumar, MD, MPH: consultant/advisor/speaker: Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Intercept, Ipsen, Madrigal, Novo Nordisk.